This post is from a suggested group
Scientific and Therapeutic Review of Tenecteplase Drug, Thrombolytic Mechanisms, and Emergency Cardiovascular Care
Tenecteplase is a genetically engineered thrombolytic agent used to dissolve blood clots in acute myocardial infarction and other thrombotic emergencies. It is a modified form of tissue plasminogen activator designed for enhanced fibrin specificity and longer half-life, allowing it to be administered as a single IV bolus rather than continuous infusion.
Mechanistically, Tenecteplase binds to fibrin within clots and converts plasminogen to plasmin, initiating fibrinolysis. Its engineered amino acid substitutions improve resistance to natural inhibitors, prolong therapeutic activity, and reduce systemic bleeding risk compared to earlier agents.
Clinical use focuses on time-critical cardiac events, where rapid reperfusion significantly improves survival. It offers advantages in pre-hospital treatment delivered by emergency medical teams, especially in regions lacking immediate access to catheterization labs.
Ongoing trials evaluate its effectiveness in ischemic stroke, pulmonary embolism, and other vascular conditions. Safety considerations remain essential, particularly regarding bleeding risks, contraindications, and dosage adjustments.